Eyestem completes Phase 1 of its RPE Cell Therapy with promising efficacy and safety outcomes
The company has completed study of the investigational RPE cell therapy, Eyecyte-RPE, and submitted the clinical study report to CDSCO for Phase 2 approval.
OneSource and Xbrane Biopharma enter into strategic biosimilars manufacturing
The partnership centers on commercial manufacturing of Xbrane’ s EUR 23 billion biosimilar portfolio, led by Ximluci, approved in Europe and pending U. S. approval.
Iom Bioworks raises Rs 4 Crore in seed round
The funds will be used for marketing, securing IP, strengthening core infrastructure, and scaling scientific and commercial teams.
BioTech
Lilly’ s once-weekly insulin demonstrates A1C reduction & a safety profile in multiple Phase 3 trials
The company evaluated safety and efficacy of investigational once-weekly insulin efsitora alfa( efsitora) in adults with type 2 diabetes.
BIOVOICENEWS. COM 09